Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer

NCT05949021 is registered in ClinicalTrials.gov with Mridula George, MD as lead sponsor.

NCT NCT05949021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05949021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple Negative Breast Cancer
Lead sponsor
Mridula George, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 7, 2023
Completion date
September 30, 2027
Enrollment
30 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer (tnbc)